Combination paclitaxel (TaxolR)-carboplatin as first-line therapy for advanced ovarian cancer
- 1 May 1997
- journal article
- Published by Elsevier in International Journal of Gynecologic Cancer
- Vol. 7 (s1) , 18-22
- https://doi.org/10.1046/j.1525-1438.7.s1.6.x
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion.Journal of Clinical Oncology, 1994
- Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristineZeitschrift für Krebsforschung und Klinische Onkologie, 1993
- Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer.Journal of Clinical Oncology, 1992
- Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group.Journal of Clinical Oncology, 1992
- Cardiac disturbances during the administration of taxol.Journal of Clinical Oncology, 1991
- Sequences of taxol and cisplatin: a phase I and pharmacologic study.Journal of Clinical Oncology, 1991
- Carboplatin dosage: prospective evaluation of a simple formula based on renal function.Journal of Clinical Oncology, 1989